Full-Time
Business Intelligence Analyst
MMS
1,001-5,000 employees
Regulatory compliance and data solutions provider
No salary listed
Remote in India
Remote
Bachelor's
 Data & Analytics (1) |
|---|
Get referred to MMS
See people who can refer or advise you
- A bachelor's degree in life sciences, statistics, data engineering, computer science, or a related field, or equivalent experience.
- Two to five years of experience in data engineering or a related discipline, preferably within clinical research or a contract research organization environment.
- Intermediate proficiency in Power BI and DAX.
- Experience designing and managing business intelligence systems, including dashboards, reporting pipelines, and data models.
- Ability to interpret and visualize data to support reporting and decision-making.
- Demonstrated ability to mentor team members and collaborate cross-functionally.
- Strong analytical, organizational, and communication skills.
- Develop requirements and specifications with stakeholders through discovery analysis of business needs and required technologies.
- Create Power BI visuals and use the DAX language.
- Prepare, correct, modify, and analyze datasets using complex analytic techniques.
- Use and understand data models.
- Develop, apply version control, and perform validation, preferably according to 21 CFR Part 11 or ISO standards.
- Work with small teams of developers from project start to finish, including managing scope and technical changes.
- Mentor technical and non-technical colleagues toward a better understanding of data science methodologies and results.
- Apply an in-depth understanding of database structure principles.
- Design and manage business intelligence systems, including dashboards, reporting pipelines, and data models.
- Interpret and visualize data to support reporting and decision-making.
- Strong R programming skills for data manipulation and analysis.
- Experience with R Shiny.
- Experience with data visualization tools such as Power BI, Tableau, D3.js, R, or R Shiny.
- Understanding of the drug development process.
- Experience working with contract research organizations or health systems and with scientific and clinical data or terminology.
- Basic understanding of CDASH, CDISC, HL7, or FHIR standards.
MMS Holdings is a global contract research organization (CRO) focused on regulatory compliance and data-driven solutions for pharmaceutical and biotech sponsors. It delivers services such as regulatory submissions, clinical trial management, data analytics, and medical writing through a service-based model that relies on established processes and experienced advisors. Its work is contract-based, often long-term, aimed at helping clients meet regulatory requirements, run trials efficiently, and advance therapies under FDA guidance. The company differentiates itself with a science-first approach, a strong track record (97% client satisfaction), and involvement in complex areas like enabling MDMA-assisted therapy research, underscoring a commitment to high-quality, compliant outcomes for sponsors globally.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Canton, Ohio
Founded
2006
Get referred to MMS
See people who can refer or advise you
Simplify's Take
What believers are saying
- Datacise reached ACDM finalist status in January 2026, validating MMS's software strategy.
- West Coast expansion before BIO 2026 targets venture-backed biotechs and faster sponsor acquisition.
- I-ACT and pediatric-trials partnerships broaden MMS's therapeutic footprint and referral network.
What critics are saying
- MMS still depends on sponsor-funded biotech budgets; trial delays hit revenue fast in 2026.
- Private-equity ownership under Lindsay Goldberg pushes margin discipline before culture and retention.
- Ascendancy in biometrics invites competition from IQVIA, Parexel, and Medidata on bigger accounts.
What makes MMS unique
- Exploristics acquisition added KerusCloud and deep biostatistics, strengthening MMS's data science edge.
- Ben Dudley became President in May 2026, sharpening global commercial and scientific execution.
- Former FDA leaders Somya Dunn and other advisors deepen MMS's regulatory credibility.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 20%1 year growth
↑ 20%2 year growth
↑ 20%MMS, a clinical research organization, has acquired Exploristics, a biostatistics and data science company. This acquisition enhances MMS' capabilities in advanced clinical trial design and data science, integrating Exploristics' KerusCloud® platform. The move expands MMS' global presence, particularly in Europe, and aims to optimize drug development strategies, reducing time and costs. Exploristics' CEO, Aiden Flynn, joins MMS as Senior VP, Head of Strategic Statistical Consulting.
On January 29, 2024, Orgenesis Inc. acquired all equity interests in Octomera LLC from MM OS Holdings, L.P., an affiliate of Metalmark Capital.
MMS Holdings Inc. plan to expand and grow in the UK and Europe to build on its teams and deliver value to its clients”
EmVenio Research announced the appointment of Mark Mackenzie, MD, as chief medical officer.
MMS Holdings, an award-winning, data-focused CRO, announced today the addition of Dr. Philip Breitfeld and Dr. Bernhardt Zeiher to its board of scientific advisors.